CA3179105A1 - The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia - Google Patents
The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia Download PDFInfo
- Publication number
- CA3179105A1 CA3179105A1 CA3179105A CA3179105A CA3179105A1 CA 3179105 A1 CA3179105 A1 CA 3179105A1 CA 3179105 A CA3179105 A CA 3179105A CA 3179105 A CA3179105 A CA 3179105A CA 3179105 A1 CA3179105 A1 CA 3179105A1
- Authority
- CA
- Canada
- Prior art keywords
- leucine
- acetyl
- acetazolamide
- administered
- ataxia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063028760P | 2020-05-22 | 2020-05-22 | |
| US63/028,760 | 2020-05-22 | ||
| PCT/IB2021/054399 WO2021234642A1 (en) | 2020-05-22 | 2021-05-20 | The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3179105A1 true CA3179105A1 (en) | 2021-11-25 |
Family
ID=76181172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3179105A Pending CA3179105A1 (en) | 2020-05-22 | 2021-05-20 | The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230201150A1 (https=) |
| EP (1) | EP4153161A1 (https=) |
| JP (1) | JP2023526517A (https=) |
| KR (1) | KR20230015433A (https=) |
| CA (1) | CA3179105A1 (https=) |
| MX (1) | MX2022014466A (https=) |
| WO (1) | WO2021234642A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886986A1 (en) * | 2018-12-06 | 2021-10-06 | IntraBio Ltd | Deuterated analogs of acetyl-leucine |
| WO2025264957A2 (en) * | 2024-06-20 | 2025-12-26 | Intrabio Inc. | Acetyl leucine for treating neurodevelopmental disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| JP2009269856A (ja) * | 2008-05-07 | 2009-11-19 | Nobufumi Ono | 異常行動防止薬及びこれを含むインフルエンザ治療薬 |
| LT2588130T (lt) | 2010-06-25 | 2016-12-12 | Shire Human Genetic Therapies, Inc. | Terapinės priemonės pristatymas cns |
| CA2825810A1 (en) * | 2011-01-28 | 2012-08-02 | Acorda Therapeutics, Inc. | Use of 4-aminopyridine to treat cerebral palsy |
| TN2016000259A1 (en) * | 2016-06-27 | 2017-10-06 | Rekik Raouf | Salbutamol (albuterol) eye protective medicament. |
| WO2018029658A1 (en) * | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| US10485790B1 (en) * | 2018-09-13 | 2019-11-26 | Syneurx International (Taiwan) Corp. | Salts of cycloserine compounds and applications thereof |
| WO2021048431A1 (en) * | 2019-09-12 | 2021-03-18 | Amabiotics | Compounds for treating ataxia |
-
2021
- 2021-05-20 US US17/999,598 patent/US20230201150A1/en active Pending
- 2021-05-20 EP EP21728642.6A patent/EP4153161A1/en active Pending
- 2021-05-20 JP JP2022571228A patent/JP2023526517A/ja active Pending
- 2021-05-20 KR KR1020227045142A patent/KR20230015433A/ko active Pending
- 2021-05-20 WO PCT/IB2021/054399 patent/WO2021234642A1/en not_active Ceased
- 2021-05-20 MX MX2022014466A patent/MX2022014466A/es unknown
- 2021-05-20 CA CA3179105A patent/CA3179105A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230201150A1 (en) | 2023-06-29 |
| WO2021234642A1 (en) | 2021-11-25 |
| MX2022014466A (es) | 2022-12-13 |
| JP2023526517A (ja) | 2023-06-21 |
| EP4153161A1 (en) | 2023-03-29 |
| KR20230015433A (ko) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI314054B (en) | Novel methods and compositions for alleviating pain | |
| EP3056200B1 (en) | Huperzine for use in treating seizure | |
| JP2010511616A (ja) | 水素化ピリド（４，３−ｂ）インドール（異性体）に基づいた認知機能および記憶を改善するための手段、当該手段に基づいた薬理学的手段、および当該手段の使用のための方法 | |
| EP2754440B1 (en) | Medicinal agent for treating amyotrophic lateral sclerosis or preventing progression of phase of amyotrophic lateral sclerosis | |
| US20180021303A1 (en) | Bkca channel activator for treating muscular disorder | |
| HK1247847A1 (zh) | 四氢-N，N-二甲基-2，2-二苯基-3-呋喃甲胺的对映体(ANAVEX2-73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途 | |
| US20230201150A1 (en) | The combination of acetyl leucine and 4-aminopyridine or acetazolamide for treating ataxia | |
| US6541513B2 (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| AU2002242296A1 (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| KR102693607B1 (ko) | 하지 불안 증후군을 치료하기 위한 치료제 | |
| WO2023215277A1 (en) | Trimeprazine for use in treating trigeminal neuralgia and for reducing pain related thereto | |
| US20020055535A1 (en) | Method for treating pain in humans | |
| KR20070083903A (ko) | 경구 효과적인 칸나비노이드 유사체 | |
| US20200281928A1 (en) | Vitamin b1 in high doses for use in the medical treatment of motor symptoms of some sporadic neurodegenerative diseases, of genetic origin, and of cluster headache and of migraine headache | |
| WO2025096942A1 (en) | Trimeprazine for use in treating pain associated with trigeminal neuralgia | |
| Lehr Jr | Therapy, neuroplasticity, and rehabilitation | |
| HUE027934T2 (en) | Combination for the prevention and treatment of behavioral, mental and cognitive disorders | |
| BR102020011146A2 (pt) | Uso combinado de substâncias mióticas anticolinesterásicas e corticosteróides para prevenção e/ou tratamento da miastenia gravis ocular | |
| HK40036165A (en) | Acetyl-leucine for use in treating restless leg syndrome | |
| HK1209058B (en) | Compositions for treating drug addiction and improving addiction-related behavior | |
| HK1209058A1 (en) | Compositions for treating drug addiction and improving addiction-related behavior | |
| HK1176285B (en) | Compositions for treating drug addiction and improving addiction-related behavior |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241227 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241227 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250509 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250509 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250509 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250723 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250723 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250723 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250723 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250723 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260409 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260409 |